Dr. Xu has more than 20 years of experience in pharmaceutical research and development. Dr. Xu worked at Archemix, Serono and Biogen as Principal Investigator or Project Leader. In 2008, Dr. Xu founded several biopharmaceuticals companies including Suzhou Alphamab and Jiangsu Alphamab. In 2019, Dr. Xu led successful Initial Public Listing for Alphamab Oncology on the Main Board of Hong Kong Stock Exchange (stock code: 9966 HK).
Dr. Xu has extensive experiences in protein engineering, antibody drug screening and engineering, and CMC, as well as animal pharmacology and toxicology. Several engineered protein drugs which Dr. Xu previously was involved in the development have been marketed or in clinical development stage in Europe and the United States. After returning to China, he has established several proprietary protein and antibody engineering platforms, successfully developed more than 20 innovative biological drug candidates and more than 30 biosimilar drug candidates, built a large-scale manufacturing base which meets international standards. He is leading the R&D and clinical development of Alphamab Oncology's 16 innovative biological oncology drug candidates.
Dr. Xu obtained his bachelor’s degree in biochemistry from Nanjing University, doctoral degree from the Institute of Biophysics of the Chinese Academy of Sciences, was a post-doctoral fellow at Harvard University. Currently, Dr. Xu holds adjunct professorship in Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, and Southeast University. He has applied more than 100 patents. Dr. Xu has been recognized by many awards including "Third place in China Entrepreneurship Competition", "2017 Suzhou Science and Technology Innovation Mayor Award", "2017 Suzhou Charismatic Science and Technology Figure", "2018 Jiangsu Top Ten Science and Technology Innovation and Entrepreneurship Figures", "2018 EBC Entrepreneur of the Year" and “The 6th Suzhou Outstanding Talent Award".
Dr. Johannes Nippgen joined the pharmaceutical industry over 15 years ago after another decade's experience as MD/PhD in clinical oncology. His industry expertise covers the clinical development and program leadership area in international biopharma and biotech companies. In his most recent position, he was heading R&D in China for the German Merck. He studied clinical medicine in Mainz, Germany, and earned his doctorate in Wurzburg, Germany. He published in various regional and international journals including the New England Journal of Medicine.
Mr. Weihao Xu has more than 10 years experiences in global capital market, equity investment and financial management. Mr. Xu held important roles in several publicly traded company and global investment companies. Prior to Alphamab Oncology, Mr. Xu served as Chief Financial Officer for CASI Pharmaceuticals and 111 Inc. In the area of investment，he served as a Portfolio Manager in Matthews International and several other international funds. Mr. Xu holds a Master of Philosophy degree in Finance and Accounting from Columbia Business School and also completed High Impact Cancer Research, a postgraduate program at Harvard Medical School.